- P-ISSN 1010-0695
- E-ISSN 2288-3339
Objectives: Objective: The purpose of this study was to confirm effect of reducing inflammation of Coptis chinensis extract -ceramide complex through the endocannabinoid system (ECS) control in atopic dermatitis. Methods: 8-week-old ICR mice were divided into normal group (Ctrl), lipid barrier elimination group (ADE), palmitoylethanolamide treated group after lipid barrier elimination (PEAT), and Coptis chinensis extract-ceramide complex applied group after lipid barrier elimination (CRA). After inducing atopic dermatitis, cannabinoid receptor (CB) 1, CB2, CD68, p-IκB, iNOS, substance P and serotonin were observed to confirm the regulation of the ECS, macrophage activity and mast cell activity. Results: CB1 and CB2 showed higher positive reactions in the CRA than in the ADE and PEAT. CD68, p-IκB and iNOS showed higher positive reaction in the ADE, PEAT and CRA than in the Ctrl, but the increase in the positive reaction was lower in the CEA compared to the ADE and PEAT. Substance P and serotonin showed higher positive reaction in the ADE, PEAT and CRA than in the Ctrl, but the increase in the positive reaction was lower in the CEA compared to the ADE and PEAT. Conclusions: The effects of Coptis chinensis extract -ceramide complex were confirmed on the regulation of the ECS, macrophage activity and mast cell activity.
1. Kim, J.H., (2004). Current understanding of atopic dermatitis. Pediatr Allergy Respir Dis, 14(1), 12-23.
2. Blume-Peytavi, U., & Metz, M. (2012). Atopic dermatitis in children: management of pruritus. J Eur Acad Dermatol Venereol, 26, 2-8. https://doi.org/10.1111/j.1468-3083.2012.04710.x
3. Lee, J.Y., & Kim, D.G. (1999). The Clinical Study of Atopic Dermatitis. J Pediatr Korean Med, 13(2), 171-86.
4. Jee, H.M., Kim, K.W., Kim, C.S., Sohn, M.H., Shin, D.C., & Kim, K.E. (2009). Prevalence of asthma, rhinitis and eczema in Korean children using the International Study of Asthma and Allergies in Childhood (ISAAC)questionnaires. Pediatr Allergy Respir Dis, 19(2), 165-72.
5. Kim, B.E., & Leung, D. (2012). Epidermal barrier in atopic dermatitis. Immunol Res, 4(1), 12-6. http://dx.doi.org/10.4168/aair.2012. 4.1.12
6. Hogan, M.B., Peele, K., & Wilson, N.W. (2012). Skin barrier function and its importance at the start of the atopic march. J Allergy, 901940 . https://doi.org/10.1155/2012/901940
7. Ahn, K.M., Kim, J.H., Kwon, H.J., Chae, Y.M., Hahm, M.I., Lee, K.J., et al. (2011). The prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in Korean children: nationwide cross-sectional survey using complex sampling design. J Korean Med Assoc, 54(7), 769-78. https://doi.org/10.5124/jkma.2011.54.7.769
8. Kim, M.J., & Lee, S.Y. (2000). A Literature Study of Atopic Dermatitis for Children. J Pediatr Korean Med, 14(2), 167-82.
9. Muluye, R.A., Bian, Y., & Alemu, P.N. (2014). Anti-inflammatory and antimicrobial effects of heat-clearing Chinese herbs: a current review. J Tradit Complement Med, 4(2), 93-8. https://doi.org/10.4103/2225-4110.126635
10. Chin, L.W., Cheng, Y.W., Lin, S.S., Lai, Y.Y., Lin, L.Y., Chou, M.Y., et al. (2010). Anti-herpes simplex virus effects of berberine from Coptidis Rhizoma, a major component of a Chinese herbal medicine, Ching-Wei-San. Arch Virol, 155(12), 1933-41. https://doi.org/10.1007/s00705-010-0779-9
11. Yu, Y.E., Park, E.Y., Jung, D.H., Byun, S.H., Kim, S.C., & Park, S.M. (2010). Antibacterial activity of oriental medicinal herb extracts against skin pathogens. J Life Sci, 20(7), 1143-50. https://doi.org/10.5352/JLS.2010.20. 7.1143
12. Kim, H.K., & Hong, S.U. (2011). The anti-inflammatory effects of Huang-Lyun (Coptidis Rhizoma, CR) on injured tissue after burn elicitation. J Korean Oriental Med, 32(2), 1-13.
13. Baron, E.D., Barzilai, D., Johnston, G., Kawashima, M., Takigawa, M., Nakagawa, H., et al. (2002). Stevens SR. Atopic dermatitis management: comparing the treatment patterns of dermatologists in Japan, U.S.A. and U.K. Br J Dermatol, 147, 710-5. https://doi.org/10. 1046/j.1365-2133.2002.04895.x
14. Salzet, M. (2000). Invertebrate molecular neuroimmune processes. Brain Res Rev, 34(1), 69-79. https://doi.org/10.1016/S0165-0173(00)00041-2
15. Pacher, P., Batkai, S., & Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev, 58(3), 389-462. https://doi.org/10.1124/pr.58.3.2
16. Kupczyk, P., Reich, A., & Szepietowski, J.C. (2009). Cannabinoid system in the skin – a possible target for future therapies in dermatology. Exp Dermatol, 18(8), 669-79. https://doi.org/10.1111/j.1600-0625.2009.00923.x
17. Miller, L.K., & Devi, L.A. (2011). The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev, 63(3), 461-70. https://doi.org/10.1124/pr.110.003491
18. Luger, T.A. (2002). Neuromediators--a crucial component of the skin immune system. J Dermatol Sci, 30(2), 87-93. https://doi.org/10. 1016/S0923-1811(02)00103-2
19. Maccarrone, M., Rienzo, M., Battista, N., Gasperi, V., Guerrieri, P., Rossi, A., et al. (2003). The Endocannabinoid System in Human Keratinocytes: Evidence that anandamide inhibits epidermal differentiation through CB1receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem, 278(36), 33896-903. https://doi.org/10.1074/jbc.M303994200
20. Karsak, M., Gaffal, E., Date, R., Wang -Eckhardt, L., Rehnelt, J., & Petrosino, S. (2007). Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System. Science, 316(5830), 1494-97. https://doi.org/10.1126/science.1142265
21. Casanova, M.L., Blazquez, C., Martinez-Palacio, J., Villanueva, C., Fernandez-Acenero, M.J., Huffman, J.W., et al. (2003). Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest, 111(1), 43-50. https://doi.org/10.1172/JCI16116.
22. Walker, J.M., & Hohmann, A.G. (2005). Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol, 168, 509-54. https://doi.org/10.1007/3-540-26573-2_17
23. Jhaveri, M.D., Richardson, D., & Chapman, V. (2007). Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol, 152(5), 624-32. https://dx.doi.org/10.1038%2Fsj.bjp.0707433
24. Tóth, B.I., Dobrosi, N., Dajnoki, A., Czifra, G., Olah, A., Szollosi, A.G., et al. (2011). Endocannabinoids Modulate Human Epidermal Keratinocyte Proliferation and Survival via the Sequential Engagement of Cannabinoid Receptor-1 and Transient Receptor Potential Vanilloid-1. J Invest Dermatol, 131(5), 1095-104. https://doi.org/10.1038/jid.2010.421
25. Tóth, K.F., Ádám, D., Bíró, T., & Olah, A. (2019). Cannabinoid Signaling in the Skin:Therapeutic Potential of the "C(ut)annabinoid"System. Molecules, 24(5), 918. https://doi.org/10.3390/molecules24050918
26. Arbabi, S., & Maier, R.V. (2002). Mitogen -activated protein kinases. Crit Care Med, 30(1), 74-9.
27. Chung, H.Y., Cesari, M., Anton, S., Marzetti, E., Giovannini, S., Seo, A.Y., et al. (2009). Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev, 8(1), 18-30. https://doi.org/10.1016/j.arr. 2008.07.002
28. Baeuerle, P.A., & Baltimore, D. (1996). NF-kappa B: ten years after. Cell, 87(1), 13-20. https://doi.org/10.1016/s0092-8674(00)81318-5
29. Aktan, F. (2004). iNOS-mediated nitric oxide production and its regulation. Life Sciences, 75(6), 639-53. https://doi.org/10.1016/j.lfs.2003. 10.042
30. Kay, A.B.(2001). Allergy and allergic diseases. First of two parts. N Engl J Med, 344, 30-7. https://doi.org/10.1056/nejm200101043440106
31. Jo, J.W., & Kim, C.Y. (2017). The Neurotransmitter Pathway of Itching. J Life Sci, 27(5), 600-10. https://doi.org/10.5352/JLS.2017